April 27-30, 2024
Barcelona, Spain

European Society of Clinical Microbiology and Infectious Diseases.

Explore more information for Gilead COVID-19 therapies
Results (7)

Pharmacokinetics, safety and tolerability of a single dose of Obeldesivir in healthy Japanese and white participants

Obeldesivir is efficacious as oral postexposure prophylaxis for Sudan ebolavirus infection in nonhuman primates

Impact of multiple-dose remdesivir, an intravenous COVID-19 antiviral, on CYP3A4 activity in healthy volunteers: a clinical drug-drug interaction (DDI) study with midazolam

Remdesivir reduces mortality in elderly patients 65+ years hospitalised for COVID-19 during Omicron

Clinical Evaluation of Drug-Drug Interactions With Obeldesivir, a Promising Oral Antiviral Treatment

Remdesivir reduces mortality in immunocompromised patients hospitalised for COVID-19 across the pandemic and endemic eras

Comparative effectiveness of remdesivir and dexamethasone combination therapy vs dexamethasone monotherapy in patients hospitalised for COVID-19